

## 31 December 2024 Quarterly Update and Appendix 4C

### US FDA clearance on track, rapid user implementation growth within core business and positive Infant App market launch

PainChek Ltd (ASX: PCK) (“PainChek” or “the Company”), developer of the world’s first smart device-based pain assessment and monitoring application, is pleased to announce its quarterly activities and cashflow report (Appendix 4C) for the quarter ended 31 December 2024.

#### Highlights

- US FDA De Novo regulatory request submitted, with confirmation from US FDA that materials supplied are complete – final decision expected by May 2025.
- Global 100,000 contracted licences with an ARR of \$4.8M once fully implemented – 22% increase on prior year.
- Global 68,458 implemented licences with an ARR of \$3.3M –and 18% increase on prior year and 11% increase in licences on the prior quarter
- Global Customer retention remains at the 85%-90% over the past year with more than 50% of existing clients now having contracted with PainChek for more than 3 years, confirming long term client retention adopting PainChek into their established processes and new regulation compliance.
- Home Care sales increase with first significant sale with Anglicare SA in Australia ~2100 home care licences
- Royal Edinburgh hospital trial commenced in UK.
- Positive results from PainChek® Infant Early Access Programme with Infant App now available on Apple App Store to drive greater recruitment.
- Infant website update and interactive videos in development to support the broader commercial launch in Q2 CY2025.
- Cumulative PainChek pain assessments reach 8,690,000 – 111% increase over the previous year.
- Customer receipts for the quarter of \$717,000.
- Recognised revenue (unaudited) for the 6 months to December 2024 is \$1,658,000 (2023: \$1,304,000), an increase of 27% over prior year.
- Raised \$5.1m by way of a fully underwritten rights issue in December 2024.

#### Commentary

Philip Daffas, PainChek CEO, commented;

“We are delighted to confirm the recent PainChek Adult App FDA De Novo regulatory clearance submission that is expected to provide the basis for expansion of the PainChek business into the US, the largest healthcare market in the world with a potential value to PainChek of \$100,000,000 per annum in aged care alone. We’ve already had initial positive feedback from FDA, confirming our documentation is complete and that the review will be managed

by the same executive who we originally met in 2019 – prior to the COVID delay. This provides us added confidence PainChek will soon become the first and only FDA regulated pain assessment App to enter the US market. We're anticipating this occurring in the first half of 2025, with our established US-based go to market partners in place.

2025 will also see the PainChek Adult App business build from the existing 100,000+ commercial licences in the aged care sector into the new and larger home care and hospital markets. This shift is based on having established solid footholds in both these markets in the past year and is being driven by new local and international government home care policies including pain assessment guidelines and funding.

Finally, the Infant App is being consumer market tested and is expected to be ready for direct-to-consumer (parental) market introduction in the second quarter of CY2025. This is a 400 million pre-verbal children marketplace with 150 million born to first time parents each year. Again, the PainChek Infant offering is a world first and seen as a highly desirable clinical tool by the parental target client base. The Company has engaged with new direct-to-consumer marketing specialists and channel partners to support the upcoming marketing and communications campaign.

The Company believes achieving each of these strategic goals over the next two quarters will drive shareholder value. On behalf of the board and broader team I'd like to also thank both our new and existing shareholders who supported the recent \$5.1 million entitlement offer, which provides PainChek with the growth capital it needs to pursue the abovementioned initiatives."

## Core market expansion and market penetration


PainChek has 100,000 contracted licences globally across almost 1,820 aged care facilities, with an ARR of \$4.8M once the licences are fully implemented. Global retention rates remain steady at 85-90%, in line with SaaS company best practice and ~6,000 new licences were contracted in the quarter. The total contracted licences remain same as previous quarter and an 18% increase on prior year.


68,458 licences, with an ARR of \$3.3M, have been implemented, a net increase of 11% over the prior quarter and 18% increase over the prior year.

The company continues to gain new clients (see regional reports below) and retain long-term customers. As at December 2024 over 50% of existing implemented customers have been using PainChek for over 3 years, confirming long term client retention and clients adopting PainChek into their established processes and new regulation compliance.


There were a significant number of implementations in the UK in the quarter during which a number of those clients reduced their total licence requirements due to internal restructuring and following a review with PainChek. Therefore, while implementations significantly increased in the UK, the overall Global number of contracted licences remained unchanged from the previous quarter. The pipeline for ANZ, UK and Canadian markets remains strong and continues to be well supported by resellers and partners.

The market penetration within aged care of the PainChek Adult App is circa 30% in Australia and 8% in the UK.





The global PainChek utilisation continues to grow, with over 8.6 million cumulative PainChek clinical assessments conducted as of 31 December 2024, an increase of 111% over the previous year and 17% over the prior quarter, reflecting continued strong growth in clinical use and implementation progress. Utility is a key driver of ongoing client retention.



## ANZ market

~63,000 ANZ contracted licences maintaining a ~30% market penetration within aged care, a 3% increase in the quarter and a 4% increase over prior year.

### Sales & Marketing

- Anglicare SA, a long standing residential aged care client of PainChek, has become PainChek's newest and largest Home Care client with 2,100 Home Care licences contracted, reaffirming the applicability in this emerging sector. The total Australian Home Care market opportunity is over 272,000 licenses.
- Building on the well-established partnership with AlayaCare in the residential aged care space, PainChek is extending its integration into AlayaCare's Home Care solution, AlayaCare Cloud, which is being released to market in February. As the largest provider of Home Care software in both the ANZ and Canadian regions, extending our partnership with this market leading partner will expedite rapid growth in the Home Care sector.
- PainChek was invited to speak on a panel at the NZACA conference on AI potential to improve healthcare in NZ. The presentation highlighted the use of AI in the PainChek tool and how it can be used to assist in care delivery and better outcomes. This led to a renewed interest in PainChek in New Zealand, leading to 4 new providers signing PainChek agreements in the quarter.
- The expansion into the disability sector includes a pilot in progress with a large disability and community provider SACare, who are established forerunners in clinical and quality safety for South Australia. SACare are part of the OnCall Group Australia (VIC/QLD), totaling over 1,200 licenses with full implementation.
- In November 2024, PainChek announced the Strategic Partnership with BestMed through a Reseller Agreement. This enables PainChek to expand its Market reach across Australia, working with the BestMed team and their established client relationships. BestMed has more than 50% market adoption across the Australian residential aged care sector including the majority of the larger aged care providers. BestMed currently work with over 6,500 clinicians and 2,800 pharmacies specializing in aged care on a daily basis.

### Operations

- ANZ clients have welcomed the new PainChek activation agreements that commenced in the last quarter. The activation agreements provide a window of time to implement licences and train users, in advance of the commencement of their contracted activation date. As a result, these clients have benefitted from a reduction in the time it takes to onboard and transform their processes, allowing a faster return on their investment and quicker collection times for PainChek.
- The partnerships with several existing large RAC providers have been strengthened by securing their Home Care business. To enable regional sales expansion, operations and product management have been working with the development team to improve product for the Home Care market; and the go to market strategies and system integration improvements to meet the needs in both the ANZ and UK Home Care markets.
- Retention remains strong in this established aged care market and in Australia over 70% of our customers licences have been in use for more than 3 years.

## UK market

UK contracted licences ~37,000 – 8% market penetration – 49% increase on prior year with implemented licences increase 110% on prior year to 23,000 licences and 31% from the previous quarter.

### Sales & Marketing:

- Bracebridge Care Group an award-winning care provider that provides residential and nursing dementia care signed for 1,062 beds
- Pipeline expansion includes pilots agreed with Avery Healthcare, Maria Mallaband Care Group, Methodist Homes, Aria Care, and the Caron group, totalling 20,667 beds upon full implementation.
- The Scottish Government is conducting a cost-benefit analysis of participating care homes in collaboration with the Scottish Care Inspectorate, with Edinburgh Napier University completing the study by the end of April. The findings, along with the Care Inspectorate's evaluation of PainChek, will be presented to the Scottish Government in a ministerial briefing, and discussions are underway for further expansion across Scotland, providing access to over 30,000 beds.
- PainChek® has been featured in The UK Sunday Times, highlighting how AI is transforming care homes in the UK. The article highlights PainChek® as a key innovation helping care staff better assess and manage pain in residents with dementia. The article can be accessed at <https://www.painchek.com/wp-content/uploads/2024/12/PainChek-Feature-in-The-Times-Inside-the-AI-care-home-the-smart-tech-making-old-people-safer-1.pdf>
- In November, the team attended the UK Dementia Congress, where Care UK, the third-largest care provider in the UK, presented outcomes from five homes in the Suffolk area. Their findings highlighted how effective pain management using PainChek has led to a reduction in both distress and the use of psychotropic medication among individuals living with dementia. The group has now expanded to over 15 care homes and continues to evaluate the use of PainChek on a larger scale.

### Operations:

- 23,000 implementations completed by the end of Q2, a 31% increase in progress from Q1
- Train the trainer strategy has continued to accelerate the pace of implementations with larger groups, including Oakland Care (657 beds), Renaissance (267 beds), and Sandstone (640 beds).
- Fortnightly webinars were launched in October 2023, with attendance continually increasing and supporting greater usage of PainChek, allowing the UK to approach 1.5 million cumulative assessments since launching in the UK market
- The gap between contracted beds and implemented beds has reduced to 6,438 beds a reduction of 8,781 in the quarter.
- All 820 beds across 20 care homes funded by South West London ICB have successfully adopted PainChek. An interim report indicates widespread usage, with outcomes highlighting fewer hospital admissions, falls, and accidents, thereby improving the quality of life for residents.

### Hospital:

- The pilot program at Edinburgh Royal Infirmary has begun following the successful integration of the TrakCare electronic medical records system by InterSystems. This integration allows pain data collected

from PainChek assessments completed by Specialist Pain Nurses in various wards to be seamlessly transferred into TrakCare. This process supports clinicians in making informed decisions regarding patient care. A successful pilot will pave the way to broader adoption across Scotland.

## North America market

### US FDA (Food and Drug Administration) regulatory clearance

In November 2024 the Company confirmed the submission of the PainChek Adult App to request US FDA De Novo regulatory clearance. This is a major milestone for the Company as the regulatory clearance will provide the basis for expansion of the PainChek business into the US, the largest healthcare market in the world with a potential value to PainChek of \$100,000,000 USD per annum in aged care alone. The FDA have already provided positive feedback by confirming our documentation is complete and that the review will be managed by the same FDA executive who we originally met in 2019 – prior to the COVID delay.

This provides us added confidence PainChek will soon become the first and only FDA regulated pain assessment App to enter the US market. We're anticipating the FDA clearance in the first half of 2025, and we have established US based go to market partners in place and are in the process of engaging with additional local US partners to rapidly access and penetrate the US market.

### North America commercial establishment

From January 2025, PainChek's business development manager will be in Canada for 6 weeks to progress the current business ops in Canada and assess a suitable North America business base, local partners and key customers. The company will also be attending the PointClickCare US client conference in April 2025 in Las Vegas.

The North American market is the largest healthcare market in the world with 2,000,000 long term care beds PainChek has already successfully integrated with PointClickCare (PCC) and that integration is being used across five Canadian aged care facilities while other pre-marketing activity with PCC has commenced.

PCC is the leading cloud-based healthcare software provider for North America's long-term and post-acute care (LTPAC) and senior care industries. PCC has 50% of the 2,000,000 US and Canadian long-term beds under licence.

## Children's and Infant App staged rollout

PainChek continues to advance the commercialisation of the PainChek® Infant app, targeting the expansive global consumer market. With an opportunity encompassing up to 400 million pre-verbal children worldwide — including 150 million born to first-time parents annually — the Infant market presents significant potential.

We've successfully completed the initial phase of testing to validate key assumptions and meet learning objectives in preparation for launching and further testing on the iOS App Store during Q1 CY2025. This phase was designed to deepen PainChek's understanding of value proposition, App usability, hesitations or concerns and pricing indicators.

In the process we have engaged with a direct-to-consumer marketing specialist in Australia and also parental specialist channel partners including Kiindred and Mamma Mia. The Company is also in the process of recruiting a global sales and marketing manager to drive the global go to market strategy.

These insights are critical to refining the app for a higher conversion rate and advancing PainChek’s path to product-market fit. To achieve this, three research methods were employed:

1. **Early Access Program (EAP):** Through the PainChek® Infant EAP, a small group of users were engaged, generating interest from 50 participants who downloaded and began using the app.
2. **Webinar with Expert Insights:** PainChek hosted a webinar featuring paediatric dietitian Karina Savage, which attracted over 70 RSVPs and 21 attendees. During the session, a survey was filled out by 15 people that provided valuable insights into PainChek’s value proposition, pricing, and the core problem it’s addressing. This will also prove to be an invaluable acquisition list when launched on the app store.
3. **Survey via Lyssna:** Using the Lyssna research platform, PainChek recruited 50 participants from its target audience to complete a detailed survey. This validated PainChek’s assumptions, refined its value proposition, addressed key audience concerns, and informed pricing strategies.

These insights are being used by PainChek to develop the communications and channels to market that resonates with its audience - showcasing a clear and compelling value proposition and designed to drive higher conversion rates.

The Infant App has been approved by Apple to be placed on the iOS App Store and will now be available for new EAP participants by February 2025 and the Google Play Store in late February. This will drive further EAP recruitment as we finalise the product and communications and pricing strategy for commercial market introduction in Australia during Q2 CY2025.

## Other business updates

### Global integration partners

Integration agreements have been signed with Camascope, Electronic Medication Admission Record (eMAR) provider and Carebeans, a Care Management System (CMS) provider, in the UK.

PainChek maintains a close partnership with CMS and eMAR providers. This strengthens the value proposition of PainChek and increases scalability to penetrate markets through the reselling or referrals from those partners looking for additional revenue streams and differentiation of product.



### Research & Development:

PainChek Children Disabilities App: PainChek announced in December the research collaboration agreement for the development of its innovative pain assessment tool for non-verbal children with disabilities had been signed with The Kids and Perth Children's Hospital (PCH), which is part of the Child and Adolescent Health Service, made possible by a \$392,820 grant from the Western Australian Government's Future Health Research and Innovation Fund.

The project is expected to be finished in about two years and prepared for commercialisation.

As previously reported, two Hollywood Private Hospital (WA) based research projects are underway:

- **Improving pain assessment for hospitalised older adults following orthopaedic surgery using a technology-driven pain assessment: An effectiveness-implementation pilot study.** The manuscript covering the effectiveness of the PainChek training is under review by the Journal of Medical and Internet Research, with data analysis of the implementation phase continuing.
- **Improving pain assessment for hospitalised older adults using a technology-driven pain assessment: An effectiveness-implementation pilot study.** A project has been established and ethical approval obtained for an effectiveness-implementation pilot study to improve pain assessment for hospitalized older adults with cognitive impairment in general medical ward using a technology-driven pain assessment tool. This will commence in February 2025.

Additional clinical studies being progressed include:

- **Improving pain assessment for patients with cognitive impairment in the emergency department using a technology-driven app that incorporates artificial intelligence: The study assessing the feasibility of using PainChek in the hospital emergency department (ED)** has commenced at Sir Charles Gairdner and Fiona Stanley Hospitals in Western Australia.
- **Evaluating the feasibility of the PainChek® Universal App as a pain assessment tool among patients in the geriatric ward in Singapore General Hospital (SGH)** Grant funding has been obtained for the implementation study of PainChek within a Geriatric/Rehabilitation Ward at Singapore General Hospital, Singapore.
- **PainChek® Infant: Assessment of Psychometric Properties in Neonates.** The study aims to evaluate the validity of PainChek Infant for the assessment of pain in neonates undergoing frenectomy. Data collection is progressing.
- **German market:** The collaborative work with the University of Applied Sciences and Arts (HSBI) Bielefeld, Germany includes the validation of the German version of PainChek in a German aged care setting. PainChek will be validated against the German version of the Pain in Advanced Dementia scale (**PAINAD-G**) also known as Beurteilung von Schmerz bei Demenz (**BESD**), which is a widely used pain assessment tool used in people living with advanced dementia in Germany with data collection now envisaged to commence February 2025.

#### Recent PainChek Related Publications

- Srivastava A, Marabelli M, Blanch-Hartigan D, Moriarty J, Carey E, Persky S, Torous J. The Present and Future of AI: Ethical Issues and Research Opportunities. Communications of the Association for Information Systems. 2025;56(1):9.
- Sada F, Chivers P, Cecelia S, Statovci S, Ukperaj K, Hughes J, Hoti K. Parental Assessment of Postsurgical Pain in Infants at Home Using Artificial Intelligence-Enabled and Observer-Based Tools: Construct Validity and Clinical Utility Evaluation Study. JMIR Pediatrics and Parenting. 2024 Dec 3;7(1):e64669.
- Mimoso I, Figueiredo T, Midão L, Carrilho J, Henriques DV, Alves S, Duarte N, Bessa MJ, Facal D, Felpete A, Fidalgo JM. Co-Creation in the Development of Digital Therapeutics: A Narrative Review. International Journal of Environmental Research and Public Health. 2024 Nov 28;21(12):1589.

## Financial Update

- The recognised revenue from customers was \$897,000 (unaudited) for the quarter, a 18% increase over the September 2024 quarter and a 36% increase over the December 2023 quarter.
- Recognised revenue (unaudited) for the 6 months to December 2024 is \$1,658,000 (2023: \$1,304,000), an increase of 27% over prior half year.
- The company raised \$5.1m by way of a fully underwritten rights issue. Of this, \$4.26m (before costs) was issued in the quarter with the balance of \$0.85m to be issued in the March 2025 quarter.

## Cashflow

- Cash reserves are \$2.9m at the end of December 2024 including \$4.67m (before costs) collected from the \$5.1m capital raise. The FY24 R&D incentive refund is being finalised for lodgement with the ATO, a claim of \$1.3m will be sought in the quarter to March 2025. In addition, there are payments from shareholders contracted to pay \$0.9m in February 2025
- Receipts from customers in the quarter were \$717,000 (Q1 FY25: \$915,000). Customers paying in advance for the PainChek subscription have an uneven distribution of renewal dates throughout the year, which accounts for some seasonality in receipts, which will not be in line with the revenue reported.
- Research and development payments were \$779,000 (Q1 FY25: \$1,057,000), the decrease follows the completion of the FDA clinical trials and report submission payment. During the 6 months to December 2024, \$784,000 was paid to suppliers for the FDA related work, this work is now complete. The company has invested over \$2.0M in the US FDA clinical trials and data collection over the last two years. Those costs will not be repeated assuming the US FDA De Novo regulatory submission is successful as future PainChek FDA new product submissions would use the De Novo clearance as a predicate and therefore be processed through the lower cost and faster track 510K clearance process.
- Advertising and Marketing payments were \$273,000 (Q1 FY25: \$195,000), the increase follows payments for the Infant App.
- Staff Costs payments were \$1,611,000 (Q1 FY25: \$1,105,000), the increase follows staff FY24 performance-based bonus payments and superannuation payments which had been deferred.
- Administration and Corporate costs payment increased to \$824,000 (Q1 FY25: \$418,000), the increase follows one off capital raise fees of \$140,000, annual insurance premiums of \$170,000 and cyber security payments.
- In accordance with ASX Listing Rule 4.7C.3, the amount of \$161,200 stated in section 6.1 of the Appendix 4C paid to related parties and their associates related to director fees and salaries for the quarter. The company made payments to directors during the period of \$161,200: \$50,000 to non-executive and \$111,200 to executive directors.

This announcement has been approved for release by the Board.

For more information:

Natalie Climo  
Company Secretary, PainChek  
[natalie.climo@boardroomlimited.com.au](mailto:natalie.climo@boardroomlimited.com.au)  
02 8016 2875

Philip Daffas  
CEO, PainChek  
[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)  
0406 537 235

## About PainChek

[PainChek](#)® is the world's first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek's AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek's detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,800 aged care facilities, with more than 8,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias
- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>

+Rule 4.7B

**Appendix 4C**  
**Quarterly cash flow report for entities**  
**subject to Listing Rule 4.7B**

Name of entity

PAINCHEK LTD

ABN

21146035127

Quarter ended ("current quarter")

31/12/2024

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
<b>1.0 Cash flows from operating activities</b>		
1.1 Receipts from customers	717	1,632
1.2 Payments for		
(a) research and development	(779)	(1,836)
(b) product manufacturing and operating costs		
(c) advertising and marketing	(273)	(468)
(d) leased assets		
(e) staff costs	(1,611)	(2,716)
(f) administration and corporate costs	(824)	(1,243)
1.3 Dividends received (see note 3)		
1.4 Interest received	10	10
1.5 Interest and other costs of finance paid	(1)	(1)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	0	0
1.8 Other (GST)	(18)	7
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(2,777)</b>	<b>(4,613)</b>

<b>2.0 Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(2)	(6)
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.2 Proceeds from disposal of:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	0	0
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(2)</b>	<b>(6)</b>

<b>3.0</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	3,956	3,956
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>3,956</b>	<b>3,956</b>

<b>4.0</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	1,723	3,562
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,777)	(4,613)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	(6)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	3,956	3,956
4.5	Effect of movement in exchange rates on cash held	(48)	(47)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>2,851</b>	<b>2,851</b>

<b>5.0</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter</b> <b>\$A'000</b>	<b>Previous quarter</b> <b>\$A'000</b>
5.1	Bank balances	2,880	1,723
5.2	Call deposits	0	0
5.3	Bank overdrafts		
5.4	Other (provide details)		
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>2,880</b>	<b>1,723</b>

<b>6.0</b>	<b>Payments to related entities of the entity and their associates</b>	<b>Current quarter</b> <b>\$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	161
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

<b>Financing facilities</b>		<b>Total facility amount at quarter end</b>	<b>Amount drawn at quarter end</b>
<b>7.0</b>		<b>\$A'000</b>	<b>\$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>			
<i>Add notes as necessary for an understanding of the position</i>			
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	<b>Total financing facilities</b>		

7.5 **Unused financing facilities available at quarter end**

7.6 Include in the below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

<b>8.0</b>	<b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,777)
8.2	Cash and cash equivalents at quarter end (item 4.6)	2,851
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (Item 8.2 + Item 8.3)	2,851
8.5	<b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	1.0
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If Item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: No. Share payments of \$854,000 are due to be received in February and a R&D Incentive refund of \$1,370,000 expected to be received end of March 2024. Payments totalling \$740,000 were made in the quarter which are non recurring (US FDA clinical trial final payments, annual insurance premiums, development and staff incentive payments).	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: The company notified shareholders in the December 2024 entitlement offer prospectus the preparation for a significant strategic financing targeting domestic and international sources.	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: Yes. There are receipts of \$2.2m due in the next quarter and the quarterly run rate of payments will decrease following the payments described in 8.6.1.	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered</i>		

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31/01/2025  
.....

Authorised by: By the board  
.....  
(Name of body or officer authorising release - see note 4)

### Notes

- 1 This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2 If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4 If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5 If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.